(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 September 2025 (04.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/181697 A1

(51) International Patent Classification:
A61K 47/56 (2017.01) *A61P 13/12* (2006.01)

(21) International Application Number:
PCT/IB2025/052068

(22) International Filing Date:
26 February 2025 (26.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/557,685	26 February 2024 (26.02.2024)	US
63/652,612	28 May 2024 (28.05.2024)	US
63/763,225	25 February 2025 (25.02.2025)	US

(71) Applicant: **BIOHAVEN THERAPEUTICS LTD.** [US/GB]; P.O. Box 173, Kingston Chambers, Road Town, Tortola, VG1110 (VG).

(72) Inventors: **BUNIN, Anna**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **DERAMON, Edward**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **SILVERMAN, Julie**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **SIMES, Miranda L.**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **SARANGI, Prabha**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US).

(74) Agent: **ZUEV, Dmitry**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2025/181697 A1

(54) Title: BIFUNCTIONAL DEGRADERS OF ANTI-PLA2R ANTIBODY

(57) Abstract: A composition of matter including an anti-PLA2R antibody-binding moiety, a cellular receptor-binding moiety which binds to hepatocytes or other degrading cells through asialoglycoprotein receptors (ASGPR) on the surface of hepatocytes or other degrading cells in a patient or subject, and optionally, a linker moiety connecting the anti-PLA2R antibody-binding moiety and the cellular receptor-binding moiety, wherein the composition of matter is useful for removing anti-PLA2R antibody in a patient or subject.